InvestorsHub Logo
Followers 0
Posts 9
Boards Moderated 0
Alias Born 05/20/2019

Re: None

Tuesday, 10/31/2023 1:54:54 PM

Tuesday, October 31, 2023 1:54:54 PM

Post# of 3833
This is the only company in a late stage clinical trial for advanced liver disease which as a clinical outcome endpoint (prevention of varices, an often fatal complication). The galectin-3 inhibitor is also showing good results for cancer immunotherapy.

The CEO of GALT takes 80% pay in shares and the Chairman is a multi billionaire financial backer of the company who buys tens of millions in GALT stock periodically.

Dr. Ben Carson is an advisor and recently joined as a board member.

The heavy insider buying is a good sign.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent GALT News